Table 2.
The clinicopathological relevance of CD56 expression in ALK+ sALCLs
| Total (%) | CD56+ group (%) | CD56- group (%) | p value | |
|---|---|---|---|---|
| Sex | 64 | 13 | 51 | 0.706 |
| Male | 47 (73.4) | 9 (69.2) | 38 (74.5) | |
| Female | 17 (26.6) | 4 (30.8) | 13 (25.5) | |
| Age | 64 | 13 | 51 | 0.427 |
| Median | 23 | 20 | 23 | |
| Range | 5–74 | 8–60 | 5–74 | |
| Stage | 46 | 13 | 33 | 0.015* |
| I-II | 26 (56.5) | 11 (84.6) | 15 (45.5) | |
| III-IV | 20 (43.5) | 2 (15.4) | 18 (54.5) | |
| Site | 64 | 13 | 51 | 0.038* |
| Nodal | 26 (40.6) | 2 (15.4) | 24 (47.1) | |
| Extranodal | 38 (59.4) | 11 (84.6) | 27 (52.9) | |
| B symptoms | 37 | 12 | 25 | 0.308 |
| With | 20 (54.1) | 5 (41.7) | 15 (60.0) | |
| Without | 17 (45.9) | 7 (58.3) | 10 (40.0) |
* Statistically significant p values are in bold